This Event Has Now Run - Thank you to our speakers, sponsors, and delegates who joined us in Boston for the Summit!

If you are interested in the 2025 event, please get in touch at 

Fast Track Your End-to-End LNP Development, Entering into Gene Therapy to Vaccination
& Beyond with Safety & IP Confidence for Accelerated Approval

Delivering the Therapeutic Potential of LNPs at Your Flagship LNP Platform

Advancing LNPs to Deliver Novel Payloads With Specificity, Stability & Scalability

The ever-growing community of LNP pioneers as tackled the challenges associated with developing safe, compliant and efficacious LNPs. Starting with the in vitro discovery of LNPs through to the manufacturing processes, with end-to-end synergy fundamental.

Industry powerhouses including Pfizer, Moderna and Alnylam came together alongside new companies to share their insights to this community such as Capstan Therapeutics, AbbVie, Mana Bio, Serina Therapeutics, Karma Biotechnologies and more.

Leading Companies Attending Included:


Expert Speakers


Industry Leaders


Roundtables & Discussions


Hours of Dedicated Networking

Your World-Class Speaker Faculty Included:

Qin Zou

Group Leader & Associate Research Fellow


Mark Brader

Biotech Product Development Scientist Group Leader


Muthiah Manoharan

Senior Vice President - Innovation Chemistry & Alnylam Distinguished Scientist

Alnylam Pharmaceuticals

Annette Bak

Head of Advanced Drug Delivery


Yanjie Bao

Senior Director - Drug Product Development & Manufacturing


Julien Couture-Senecal


Azane Therapeutics

Randall Moreadith

Chief Development Officer

Serina Therapeutics

Lin-Xian Li

Co-Founder & CEO

Innorna Co. Ltd

What Was On?

More than just a meeting...

It has been fantastic to see our community grow over the years and continue to advance the development of LNPs.

In addition to the unrivalled scientific content in the form of presentations, panels and roundtable discussions, there was a variety of extra experiences allowing for maximum ROI out of your time at the conference.

Screenshot 2023-11-15 085456

4-Track Conference

The flagship summit returned, bringing back it's famed end-to-end conference programme full of unrivalled scientific content in the form of presentations, panels and roundtable discussions. This year, 4 parallel tracks of content were provide for all members of the team.

Screenshot 2023-11-15 085427

New! LNP 101 Day

Our new-for-2024 Pre-Conference LNP 101 Day took place before the main conference programme kicked off, giving you and your team a solid foundation for leveraging LNPs as a powerful delivery vehicle.

Lunch Briefing 2

4-Track Workshop Day

Our Pre-Conference Workshop Day provided a deep dive into key challenges within the space across Discovery & Screening, Formulation & Delivery, Characterization & Analytical Development and Process Development & Manufacturing.


New! IP Patenting & Commercial Partnerships Day

With a volatile LNP landscape and litigation more rife in the industry than ever, this was your unique chance to enhance your understanding of the intellectual property landscape in the LNP field, gaining clarity on collaborative practices while ensuring compliance with legal boundaries.

Poster Session 2

Poster Session

Interested in hearing what your peers are up to, or even sharing research of your own? Our poster session shared the latest innovations as part of the main conference programme with no extra charge.

Drinks Reception 2

Networking Opportunities

Nothing says LNP Formulation & Process Development Summit like dedicated networking opportunities! This year saw drinks receptionsspeed networking opportunities, lunch briefings and more with 400+ biopharma experts dedicated to progressing LNPs.

Screenshot 2023-11-15 084640
Screenshot 2023-11-15 084732
Screenshot 2023-11-15 084834
Screenshot 2023-11-15 084937

"Hearing from state-of-the-art scientists and technologies at the front tier of LNPs production, shelf-lie and targeting approaches."

Dan Peer, Vice President for Research & Development,Tel Aviv University

"Lipid Nanoparticles and mRNA therapeutics have entered an exciting stage of development and public awareness.
Bringing together key experts from various stages of discovery, scale-up and manufacturing is important to help spread knowledge and aid further development and utilization of this versatile drug modality"

Michael Munson, Senior Research ScientistAstraZeneca

Other Events in the Series